Recursion Reports Median 47% Reduction in Polyp Burden Among FAP Patients
Key Facts
Updated results from the TUPELO study showed that REC-4881 was associated with a median 47% reduction in total polyp burden after 12 weeks of treatment, according to a Recursion filing with the U.S. Securities and Exchange Commission. The October analysis included 16 evaluable patients, 87% of whom recorded a reduction in burden. The company said the result was consistent with a median 43% reduction in its previous update, which included 12 patients. The latest cohort’s results come as the number of evaluable patients expanded, with the clinical measure remaining the change in the sum of polyp diameters. The study targets familial adenomatous polyposis, known as FAP, a disease for which the company said no approved drug treatments are available.
TUPELO was designed to evaluate REC-4881 at a dose of 4 mg once daily for 12 weeks, followed by 12 weeks without treatment. Polyp burden was measured at baseline and then at weeks 13 and 25, allowing changes to be tracked during treatment and after it stopped. After 12 weeks off treatment, 85% of evaluable patients remained below their baseline polyp burden; the number was 11 of 13 at week 25. This result provides follow-up to the reduction recorded during treatment, measuring whether burden remained below its starting point after dosing ended. These figures apply to patients who could be evaluated in the study and do not mean that all participants had the same response.
Reported reductions extended to different parts of the gastrointestinal tract. In the upper tract, 12 of 13 evaluable patients recorded a reduction after 12 weeks, with a median reduction of 55%. After the off-treatment period, 11 of 12 patients remained below baseline at week 25, or 92%, according to the filing. In the lower tract, burden fell in 9 of 11 patients with measurable burden, or 82%, and the median reduction was 50%. These results distinguish between disease locations, with the number of evaluable patients varying in each analysis.
A separate analysis covered polyps larger than 5 mm at baseline, the category addressed in the company’s results for larger polyps. The number of these polyps fell in 6 of 8 patients after 12 weeks of treatment. Four of those patients recorded a reduction of at least 80% in the number of larger polyps. These data accompany measurements of overall burden and results by disease location, but relate to a small patient subgroup. The updated results were presented in a presidential session at the CGA-IGC meeting by Lisa Boardman, a professor of medicine at Mayo Clinic.
Monitoring polyp burden is important in a disease that, a study investigator said, still requires major surgeries and repeated endoscopic examinations, in the absence of a drug approved by the U.S. Food and Drug Administration in the United States. The investigator said: "We still, at least in the United States, lack an FDA-approved drug; we still refer patients with FAP for major surgeries and perform repeated endoscopic examinations." Recursion estimated in its October filing that the disease affects more than 50,000 people in the United States and EU5 countries. It also said REC-4881 received orphan drug and fast track designations from the U.S. Food and Drug Administration. In a natural history analysis cited by the company, average annual polyp burden increased 33% among 35 patients with upper gastrointestinal tract involvement and 88% among 28 patients with lower tract involvement.
In its previous filing, Recursion expected to begin a registrational trial in the second half of 2027, linking that timeline to the outcome of ongoing discussions with the U.S. Food and Drug Administration. The company said details of the timing and plan remain subject to the outcome of those discussions. Starting the registrational trial is the next step identified in the filing for REC-4881 after the TUPELO results. This expectation alone does not establish that the start date has been finalized or that the trial design has been agreed. The previously announced timing remains the second half of 2027.